

September 8, 2021



# PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box<sup>®</sup>, today announced that it will be presenting at the H.C. Wainwright 23<sup>rd</sup> Annual Global Investment Conference to be held virtually September 13-15, 2021.

PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, who will deliver a presentation about PharmaCyte and participate in virtual meetings with institutional investors throughout the conference, said, "We are extremely honored to present at H.C. Wainwright's 23<sup>rd</sup> Annual Global Investment Conference. PharmaCyte is forever grateful to H.C. Wainwright for bringing institutional investors to our door so that we could present our story in two separate capital raises that generated about \$90 million."

Mr. Waggoner continued, "For the first time in PharmaCyte's history, we have the opportunity to develop treatments for cancer, diabetes, and malignant ascites fluid without being constrained by finances or the need to raise additional capital. We owe that to H.C. Wainwright and its institutional clients. Presenting at the firm's Global Investment Conference gives PharmaCyte a platform to continue to tell our story and drive attention to the work we're doing in developing treatments for hard-to-treat diseases."

Mr. Waggoner's presentation will provide an overview of the Company's business. It will be available on-demand through the H.C. Wainwright portal beginning on Monday, September 13, 2021, at 7:00 a.m. EDT.

Webcast link: <https://journey.ct.events/view/bd2225da-2507-4a3b-a261-019955f8ef40>

An archive of the presentation will be made available for 90 days on the Company's website under the Media section at <https://PharmaCyte.com/media>.

To learn more about PharmaCyte's pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company's documentary video complete with medical animations at:

<https://www.PharmaCyte.com/Cancer>

## About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box<sup>®</sup>." This technology is being used as a platform upon

which therapies for several types of cancer and diabetes are being developed.

PharmaCyte's therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient's tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a "bio-artificial liver" and activate the chemotherapy drug at the site of the cancer. This "targeted chemotherapy" has proven effective and safe to use in past clinical trials and we believe results in little to no treatment related side effects.

PharmaCyte's therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. The encapsulation of the cell line will be done using the Cell-in-a-Box<sup>®</sup> technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a "bio-artificial pancreas" for purposes of insulin production.

### **Safe Harbor**

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to raise the necessary capital to fund our operations and to find partners to supplement our capabilities and resources, our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.

More information about PharmaCyte Biotech can be found at <https://PharmaCyte.com>  
Information may also be obtained by contacting PharmaCyte's Investor Relations Department.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210908005467/en/>

### **Investor Relations:**

Dr. Gerald W. Crabtree

PharmaCyte Biotech, Inc.

Telephone: 917.595.2856

Email: [InvestorRelations@PharmaCyte.com](mailto:InvestorRelations@PharmaCyte.com)

Source: PharmaCyte Biotech, Inc.